CIPLA : USFDA INSPECTION AT INVAGEN FACILITY CLASSIFIED VAI

• Cipla Limited provided an update on the USFDA inspection at its wholly owned subsidiary, InvaGen Pharmaceuticals Inc.'s, manufacturing facility in Central Islip, New York, USA. • The inspection was conducted from July 13, 2026, to July 17, 2026 (EDT). • Following the inspection, the USFDA, via communication dated August 28, 2026, has classified the inspection as Voluntary Action Indicated (VAI). Impact: USFDA inspection at InvaGen facility classified as VAI.

Cipla Limited

Open attachment

← Back to feed